Stanford University School of Medicine
The Stanford Cancer Institute at Stanford University School of Medicine
Racial and ethnic diversity is critical to the success of cancer clinical trials. Asian Americans, like other ethnic groups, have low recruitment, accrual and retention rates in cancer clinical trials. This represents a significant challenge on a national level for health advocates, healthcare institutions and the National Cancer Institute. To improve communication and awareness of clinical trials for Asian American patients, it is important to increase learners’ knowledge about cancer clinical trials and cultural humility. This online course will educate healthcare providers and allied health professionals about cancer clinical trials and cultural humility skills as well as provide educational resources and tips for reinforcing change in practice to improve outcomes in Asian American clinical trial participation.
This course is designed to meet the educational needs of a national audience of physicians and allied health professionals who specialize in family practice, primary care, internal medicine and oncology.
Please review all of the information on this page before clicking the Courseware tab at the top of the page to begin the course.
At the conclusion of this activity, participants should be able to:
The following planner and speaker indicated that he has relevant financial relationships with industry to disclose relative to the content of this activity:
George A. Fisher Jr., MD, PhD
Professor of Oncology
Faculty Director, Stanford Cancer Clinical Trials Office
Stanford Univeristy School of Medicine
Contracted Research for clinical trials with Genentech, Novartis, Bristol, Ipsen, Tercica, Gilead and Newlink
The following planners, speakers and reviewer have indicated that they have no relationships with industry to disclose relative to the content of this activity:
Kim F. Rhoads, MD, MS, MPH, FACS
Assistant Professor, Surgery
Director, Community Partnership Program, Stanford Cancer Institute
Stanford Univeristy School of Medicine
Angela Sun, PhD, MPH
Founder & President, Asian Alliance for Health, Inc.
National Outreach Core Director, AANCART
Miriam Bischoff, MS, MBA
Executive Administrative Director, Clinical Research, Stanford Cancer Institute
Rachel J. Mesia, MPH
Program Coordinator, Stanford Cancer Institute
Joyce Cheng, MS
Program Manager, Asian Alliance for Health
Outreach Core Community Director-San Francisco, AANCART
Charlene Cuaresma, MPH
Outreach Core Community Director-Hawaii, AANCART
Julie Dang, MPH, CHES
Admin Core Director and Community Health Educator, AANCART
May Louie Sung, MPH
Outreach Core Co-Director, AANCART
Jamie Felicitas, BS
Web Tool Project Manager, APICEM
Duong Ton, BA
Sr. Community Health Program Representative, AANCART
Parichart Sabado, MPH
Outreach Core Community Director, Los Angeles AANCART
Tina Tran Fung, MPH
Community Advisory Group Member, AANCART
Penny Lo, BS
Outreach Core Community Director-Sacramento, AANCART
Community Advisory Group Member (Ex-Officio), AANCART
Jann Murray-Garcia, MD, MPH
Betty Irene Moore School of Nursing, University of California, Davis
Tung Nguyen , MD
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
The Stanford University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Stanford University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The California Board of Registered Nursing recognizes that Continuing Medical Education (CME) is acceptable for meeting RN continuing education requirements as long as the course is certified for AMA PRA Category 1 Credits™ (rn.ca.gov). Nurses will receive a Certificate of Participation following this activity that may be used for license renewal.
The Stanford University School of Medicine has received and has used undesignated program funding from Pfizer, Inc. to facilitate the development of innovative CME activities designed to enhance physician competence and performance and to implement advanced technology. A portion of this funding supports this activity.
California Assembly Bill 1195 requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. It is the intent of the bill, which went into effect July 1, 2006, to encourage physicians and surgeons, CME providers in the State of California and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population through appropriate professional development. The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area. The Stanford University School of Medicine Multicultural Health Portal also contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws. You are encouraged to visit the portal: http://lane.stanford.edu/portals/cultural.html
If you are having technical problems (video freezes or is unplayable, can't print your certificate, etc.) you can submit a Help Request to the OpenEdX Team. If you have questions related to CME credit, requirements (Pre-test, Post-test, Evaluation, Attestation) or course content, you can contact the CME Online support team at email@example.com
Chen A. The legal framework for language access in healthcare settings: Title VI and beyond. Journal of General Internal Medicine. 2007:22(2): 62-367.
Epner DE, Baile WF. Patient-centered care: the key to cultural competence. Annals of Oncology. 2012;23(suppl 3):33-42.
Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, et al. Phase 0 clinical trials: conceptions and misconceptions. The Cancer Journal. 2008;14(3):133-137.
Lara PN, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, et al. Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. Journal of Clinical Oncology. 2005;23(36):9282-9289.
Okines AF, Cunningham D. Trastuzumab in gastric cancer. European Journal of Cancer. 2010;46(11):1949-1959.
Symonds RP, Lord K, Mitchell AJ, Raghavan D. Recruitment of ethnic minorities into cancer clinical trials: experience from the front lines. British Journal of Cancer. 2012;107(7):1017-1021.
©2015 Stanford University School of Medicine